Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
Researchers at Kumamoto University, Japan have revealed that DNA methylation occurs in the gene that codes serotonin transporter (SERT), a protein that regulates neurotransmitter transmission, in schizophrenia and bipolar patients.
Researchers at Orygen have found that some young people with early stage first episode psychosis (FEP) can experience reduced symptoms and improve functioning without antipsychotic medication when they are provided with psychological interventions and comprehensive case management.
A review published in the current issue of Psychotherapy and Psychosomatics analyzes the obsessions and compulsions associated with the use of clozapine, an antipsychotic drug,
A new research paper published in the journal L'Encéphale in May 2020 reports on the planned ReCoVery Study, which will examine the possibility of repurposing the antipsychotic drug chlorpromazine for the treatment of COVID-19.
An estimated 70–80% of ventilated patients will experience ICU delirium, which causes patients to enter a confused state and can lead to long-term cognitive impairments and memory deficits. GlobalData, therefore, expects to see an increase in the administration of pharmacological treatments for ICU delirium as the COVID-19 outbreak continues.
In recent years, genome-wide association studies (GWAS) have identified many different genetic variants associated with schizophrenia.
Around four in a thousand people worldwide suffer from schizophrenia, according to scientific estimates. The disease affects people from all walks of life, including Vincent van Gogh, the painter Agnes Martin, mathematician John Nash and Eduard Einstein, a son of the great physicist. The disease touches men and women equally.
A new study published in the journal Science shows that brain stimulant drugs like Ritalin, often used to treat concentration problems in conditions like attention deficit hyperactivity disorder (ADHD), work in a different way than commonly thought.
A new Japanese study in mice published in the journal Nature indicates that the cause of the profound mental disturbance termed psychosis could be due to defects in the functioning of specialized nerve cells deep inside the brain, and due to some types of learning behavior. This could help understand how delusions arise in psychosis or schizophrenia, and eventually to develop therapies for these conditions.
Neurotransmitters are chemicals that transmit signals between neurons or from neurons to other cells. They interact with specific receptors found in the brain of humans and animals, controlling a variety of biological processes, e.g. fear, anger, pleasure, memory, energy, appetite and sleep.
Bad dreams or nightmares affect not only children but adults, too. Haunting nightmares can affect a person’s sleep quality and duration, but is it possible to turn off a nightmare while it is happening?
Published in Psychological Medicine, the research used fMRI scans to examine the brain activity of 13 people with a diagnosis of psychosis under the influence of a single dose of CBD or placebo and 16 controls whilst they were undertaking a memory task.
Rutgers researchers have found that a Texas strategy to reduce anti-psychotic medication for children can serve as a model for other state Medicaid programs.
Disparities in drug prescribing suggest that black and Asian people with dementia are not receiving the same quality of care as their white peers, according to a new UCL-led study in the UK.
The use of antipsychotics is associated with increased risks of head and brain injuries among persons with Alzheimer's disease, according to a recent study from the University of Eastern Finland. The risk increase was highest at the initiation of antipsychotic use.
A team of researchers have found that persons with schizophrenia may have lower levels of certain specific proteins that show up on their brain scans. This could help as diagnostic tools, say experts. The new study titled, “Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats”, is published in the latest issue of the journal Nature Communications.
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia.
Use of antipsychotic medications was associated with an increased risk of head injuries in a study of individuals with Alzheimer's disease. The findings are published in the Journal of the American Geriatrics Society.
Delirium (sudden confusion or a rapid change in mental state) remains a serious challenge for our health care system.
Some patients skip telling their doctors about the drugs and medications they are consuming. A new study shows that these patients are at a greater risk of unpleasant and sometimes dangerous drug-drug interactions as well as addictions. The study was published in the latest issue of The Journal of the American Osteopathic Association. The study is titled, “Role of opioid-involved drug interactions in chronic pain management”.